A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity-Reference-Cited by-同舟云学术

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Published:2005-02 Issue:2 Volume:16 Page:282-288
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Borner M.M.,Bernhard J.,Dietrich D.,Popescu R.,Wernli M.,Saletti P.,Rauch D.,Herrmann R.,Koeberle D.,Honegger H.,Brauchli P.,Lanz D.,Roth A.D.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/16/2/282/327374/mdi047.pdf

Reference24 articles.

1. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial;Douillard;Lancet,2000

2. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer;Saltz;Irinotecan Study Group. N Engl J Med,2000

3. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin. A randomised crossover trial in advanced colorectal cancer;Borner;Eur J Cancer,2002

4. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study;Van Cutsem;J Clin Oncol,2001

5. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials;Twelves;Eur J Cancer,2002

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biweekly cetuximab in combination with capecitabine and oxaliplatin (XELOX) or irinotecan (XELIRI) in the first-line and second-line treatment of patients with RAS wild-type metastatic colorectal cancer;ecancermedicalscience;2022-12-15

2. A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials;American Journal of Clinical Oncology;2022-07-15

3. Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review;Cancers;2022-05-17

4. Colorectal Cancer;Abeloff's Clinical Oncology;2020

5. Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study);International Journal of Clinical Oncology;2019-05-29